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Two herpes simplex virus type 1 ribonucleotide reductase null mutants, hrR3 and ICPgA, produced cutaneous lesions 
in guinea pigs as severe as those of wild-type strains. The lesions induced by hrR3 resulted from in vivo replication of 
the mutant virus, suggesting that this virus-encoded enzyme is nonessential for virus replication in guinea pigs. o 1sss 
Academic Press. Inc. 
The enzyme ribonucleoside diphosphate reductase 
(ribonucleotide reductase, EC 1.17.4.1) plays an es- 
sential role in the de nova synthesis of mammalian 
DNA, catalyzing the reduction of ribonucleoside di- 
phosphates to 2’-deoxyribonucleoside diphosphates 
(I, 2). Herpes simplex virus type 1 (HSV-1) encodes its 
own unique ribonucleotide reductase which catalyzes 
the same reaction but which differs biochemically from 
its mammalian counterpart (3-6). In marked contrast to 
the mammalian enzyme which is highly regulated by 
nucleoside triphosphates, the viral enzyme is relatively 
free of allosteric control by dATP and dlTP (3, 4). 
The utilization of the HSV-1 ribonucleotide reductase 
as a target for the design of antiviral drugs has at- 
tracted a great deal of interest recently (7-9). For exam- 
ple, we and others have shown that 2-acetylpyridine 
thiosemicarbazone and many of its congeners are in- 
hibitors of the viral reductase (lo- 13) and show sig- 
nificant antiviral activity both in vitro and in vivo (9, 14, 
75). The usefulness of this enzyme as a target for the 
design of human antivirals has not been fully ascer- 
tained, however. The viral reductase with its lack of al- 
losteric regulation undoubtedly enhances virus replica- 
tion by increasing the deoxynucleotide pools utilized 
for viral DNA synthesis. Nutter and Cheng (1) have 
pointed out, however, that cellular DNA can be broken 
down within infected cells by virus-induced deoxyribo- 
nucleases as an alternate means of maintaining deoxy- 
nucleotide pools. Recent findings by Goldstein and 
Weller (16, 17) utilizing viral ribonucleotide reductase 
mutants indeed have substantiated the theory that the 
HSV-1 enzyme is nonessential for the in vitro replica- 
tion of this virus. In the present study we have exam- 
ined these reductase mutants in a cutaneous herpes 
guinea pig model to investigate whether the viral reduc- 
tase plays an essential function in virus replication in 
vivo . 
Female standard Hartley and hairless [Crl:IAF 
(HA)BR] guinea pigs were obtained from Charles River 
’ To whom requests for reprints should be addressed. 
Laboratories (Wilmington, MA). Protocols using stan- 
dard guinea pigs have been described in detail else- 
where (75). Procedures used with hairless guinea pigs 
were identical except for the exclusion of steps used 
to remove the animals’ hair. In brief, animals were an- 
esthetized, inoculated intradermally with virus at a titer 
of 3 x 1 O6 PFU/ml, and then observed daily for the pro- 
duction of lesions. 
In our initial test of in viva activity, separate areas on 
the backs of hairless guinea pigs were inoculated with 
the S-l 48 strain of HSV-1 commonly used in our animal 
model (15) the KOS strain of HSV-1 (from which the 
ribonucleotide reductase mutants were derived), and 
the reductase mutants hrR3 (16) and ICP6A (17). hrR3 
is an insertion mutant in which the /acZ gene from 
Escherichia co/i has been inserted within the coding 
region of ICP6, one of the two subunits of the viral re- 
ductase. The mutant produces a fusion protein in vitro 
which expresses P-galactosidase activity but no ribo- 
nucleotide reductase activity. ICPGA is a deletion mu- 
tant in which 90% of the ICP6 coding region has been 
excised. Again, no viral reductase activity is detectable 
in vitro following infection with this mutant. Lesions de- 
veloping at the inoculation sites were scored daily for 
10 days using the scoring system of Alenius and oberg 
(18) and a statistical program was utilized to analyze 
the data using techniques of profile analysis, paired t 
tests, and analysis of variance. Figure 1 illustrates that 
all four viruses induced vesicle formation in this model. 
A comparison of the individual curves revealed that the 
null mutants, in fact, were more expressive than either 
of the standard strains in this particular experiment (P 
& 0.002). Given the lack of statistical significance ob- 
served in other experiments, however, we believe this 
observation of differences in lesion severity between 
virus strains to be coincidental. Both mutants also were 
capable of inducing lesions in the standard guinea pig 
(data not shown). 
To substantiate that the formation of lesions by hrR3 
was a result of virus replication, three different meth- 
ods were employed: (1) In the first, an aliquot of hrR3 
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FIG. 1. Lesion formation in hairless guinea pigs by HSV-1 ribonu- 
cleotide reductase null mutants. Guinea pigs were inoculated intra- 
dermally with virus on Day 0 and the resultant lesions scored daily. 
was heated at 95” for 25 min while another aliquot was 
kept on ice. Each of the samples then was used to in- 
oculate a standard guinea pig. Lesions developed on 
only the section receiving unattenuated virus, indicat- 
ing that lesion formation was not merely a nonspecific 
immune response to the inoculation procedure or to 
foreign protein. (i/) In the second method, a standard 
guinea pig was inoculated with hrR3 and sacrificed 3 
days postinfection. Areas of virus-inoculated skin were 
excised and homogenized as detailed in Shipman eta/. 
(76). Homogenates were assayed for plaque-forming 
ability on an established line of African green monkey 
kidney (BSC-1) cells essentially as described previously 
(79) except that following a 4-day incubation of the cell 
monolayers with virus 1.5 ml of a HEPES-buffered sa- 
line solution (20) containing 0.3 mg 5-bromo-4-chloro- 
3-indolyl-/3-o-galactoside (X-gal; Sigma Chemical Co., 
St. Louis, MO) and 0.00125% neutral red were added 
to each well of the six-well tissue culture plate. Plaques 
were visualized within 3 days and all plaques devel- 
oped a characteristic blue color upon staining, result- 
ing from conversion of the colorless chromogenic sub- 
strate X-gal to a colored product by the &galactosidase 
fusion protein induced by hrR3. Monolayers infected 
with KOS stock virus produced plaques which re- 
mained colorless upon staining with X-gal. The possi- 
bility that hrR3 obtained from skin samples represented 
residual virus inoculum was considered highly unlikely 
due to the thermosensitive nature of HSV-1. Calcula- 
tions based upon a reported half-life at 37” of 1.5 (21) 
to 3 (22) hr suggested that the original inoculum was 
fully inactivated within 24 hr-2 days before skin sam- 
ples were harvested. (ii/) In the third method used to 
substantiate that lesion formation by hrR3 was a result 
of virus replication, hairless guinea pigs were inocu- 
lated with either hrR3 or KOS and sacrificed 4 days 
postinfection. Areas of virus-inoculated skin were ex- 
cised and processed using a modification of methods 
described by Ho and Mocarski (23). Tissue was fixed 
15 min in 0.5% glutaraldehyde in phosphate-buffered 
saline (1 mM MgC12, 137 mM NaCI, 4 mM KCI, 8 mM 
Na,HPO,, 1.5 mM KH,PO,), washed free of glutaralde- 
hyde, embedded in O.C.T. embedding medium (Miles 
Scientific, Naperville, IL), and frozen with liquid nitro- 
gen. Thin tissue sections (10 pm) were cut, collected 
onto glass slides, and dried. Slides were incubated 
overnight in phosphate-buffered saline containing 2.4 
mM X-gal, 12.5 mM K,Fe(CN),, and 12.5 rnM 
K,Fe(CN), and then counterstained with Harris’s hema- 
toxylin solution (24). Figure 2 illustrates the staining 
pattern obtained from a skin section taken from an 
hrR3-infected animal. Against a violet background of 
nuclear staining by hematoxylin can be seen a tur- 
quoise viral lesion, indicative of the presence of j3-ga- 
lactosidase activity. This finding indicates that the ge- 
netically engineered hrR3 genome was transcribed 
and the fusion protein translated in vivo. The fact that 
the entire vesicle was stained blue rather than just indi- 
vidual cells initially infected suggests that the mutant 
had undergone at least one lytic cycle of replication. 
Skin sections containing lesions induced by the KOS 
strain of HSV-1 did not stain blue upon incubation with 
X-gal nor was any nonspecific blue staining observed. 
Taken together these three observations indicate that 
the reductase mutant hrR3 is fully capable of replicat- 
ing and producing cytopathology in the guinea pig. 
The demonstration of unimpaired in vivo activity by 
ribonucleotide reductase null mutants contrasts mark- 
edly with the recent findings of other investigators. 
Cameron et a/. (26) have reported that the virulence of 
two temperature-sensitive reductase mutants was se- 
verely impaired in mice. Examination of ICPGA and KOS 
in mice by Coen and co-workers (26) revealed that the 
mutant, but not the parent strain, was severely im- 
paired in its ability to replicate in the eye and in trigemi- 
nal ganglia. The contrasting effects in different animal 
species also holds true in vitro. Coen and co-workers 
found that ICPGA replicated less efficiently in vifro in 
cells of murine lineage than of simian origin. Similarly, 
we determined the virus titers of our mutant stock solu- 
tions using monolayer cultures of mouse embryo fi- 
broblasts (3T3; provided by Dr. C. T. Hanks, The Uni- 
versity of Michigan), guinea pig lung cells (JH4; ob- 
tained from the American Type Culture Collection, 
Rockville, MD), African green monkey kidney cells 
(BSC-1; American Type Culture Collection), and human 
foreskin fibroblasts (HFF) by methods previously re- 
ported (19). We found that ICP6A and hrR3 both repli- 
cated 99% less efficiently in murine cells than in guinea 
pig, simian, or human cells (data not shown). Given the 
observations reported herein further investigation is 
warranted to ascertain whether the HSV-1 ribonucleo- 
tide reductase is essential for the in vivo replication of 
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FIG. 2. Histochemical staining of an hrR3-induced lesion from guinea pig skin. Infected tissue was fixed and sectioned, stained with X-gal, 
and then counterstained with Harris’s hematoxylin solution. 
pathogenicity of this virus in other animal species and 
humans. 
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